Last reviewed · How we verify
TransCon hGH
TransCon hGH is a long-acting human growth hormone (hGH) analog that uses a proprietary technology called TransCon to extend its half-life.
TransCon hGH is a long-acting human growth hormone (hGH) analog that uses a proprietary technology called TransCon to extend its half-life. Used for Treatment of growth hormone deficiency in children and adults.
At a glance
| Generic name | TransCon hGH |
|---|---|
| Also known as | ACP-011 |
| Sponsor | Ascendis Pharma A/S |
| Drug class | Growth hormone analog |
| Target | Human growth hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
This allows for once-weekly dosing, mimicking the natural pulsatile secretion of hGH. TransCon hGH is designed to provide sustained growth hormone levels, potentially improving growth outcomes in patients with growth hormone deficiency.
Approved indications
- Treatment of growth hormone deficiency in children and adults
Common side effects
- Injection site reaction
- Hypersensitivity reaction
- Gallbladder disease
Key clinical trials
- A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
- A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency (PHASE3)
- A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency (PHASE3)
- A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial (PHASE3)
- A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency (PHASE3)
- A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) (PHASE3)
- Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency (PHASE3)
- A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone Deficiency (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TransCon hGH CI brief — competitive landscape report
- TransCon hGH updates RSS · CI watch RSS
- Ascendis Pharma A/S portfolio CI